Acyclic Carbon To Carbon Unsaturation Patents (Class 514/733)
  • Patent number: 10675318
    Abstract: A composition for promoting antioxidative activity includes an effective dose of Rhodiola extract, an alpha-Glycerophosphocholine (alpha-GPC), and a pharmaceutically acceptable vehicle or salt thereof. Based on animal experiments, the combination of rhodiola extract and alpha-Glycerophosphocholine provides high antioxidative activity.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: June 9, 2020
    Inventor: Fu-Hsing Huang
  • Patent number: 10588979
    Abstract: The present invention discloses a topical composition comprising terpene blend and cannabidiol (CBD) or a derivative thereof, useful for managing pain, the treatment or prevention of inflammatory skin disorders, and treatment methods thereof. The composition includes 2-pyrrolidone-5-carboxylic acid and a blend of antioxidants to optimize tissue health.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 17, 2020
    Inventors: Cody D. Freeze, Allison N. Freeze
  • Patent number: 10576157
    Abstract: A method for delivering therapeutics includes infusing a hydrogel with cannabis; and contacting the hydrogel infused with cannabis into a human which causes the controlled timed releasing of the cannabis with hydrophobic molecules to permeate through a lipid pathway.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 3, 2020
    Inventor: Shabana Naheed
  • Patent number: 10472652
    Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 12, 2019
    Assignee: TEEWINOT TECHNOLOGIES LIMITED
    Inventors: Richard Peet, Malcolm J. Kavarana, Robert Winnicki, Marc Donsky, Mingyang Sun
  • Patent number: 10456343
    Abstract: The instant disclosure relates to microemulsion compositions comprising polydatin, which are useful as cosmetic and/or pharmaceutical compositions for application to the skin and/or hair. The microemulsion compositions comprise: (a) polydatin; (b) optionally, niacinamide; (c) optionally, baicalin; (d) one or more oils; (e) water; and (f) one or more emulsifiers. Furthermore, the ratio of the total amount of the one or more emulsifiers to the total amount of the one or more oils is typically 1.7 to 2.5.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: October 29, 2019
    Assignee: L'OREAL
    Inventors: Zhi Pan, Yan Yu, Anne-Laure Suzanne Bernard
  • Patent number: 10398776
    Abstract: A phonophoretic cannabidiol composition comprises an amount of cannabidiol, an amount of a glucose source, such as honey, an amount of aloe vera, and amounts of one or more of glucosamine, methylsulfonylmethane, and chondroitin. A transdermal delivery system for administration of a phonophoretic cannabidiol composition includes a phonophoretic cannabidiol composition, a laser generator comprising an emitter which generates and directs a laser beam to the treatment area, and an ultrasound generator comprising a transducer which generates and transmits a plurality of ultrasonic waves to the treatment area. A method for transdermal delivery of a phonophoretic cannabidiol composition includes selecting laser pretreatment parameters, directing a laser beam to the treatment area, applying an amount of a phonophoretic cannabidiol composition to a treatment area, selecting ultrasonic treatment parameters, and, transmitting a plurality of ultrasonic waves to the treatment area.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: September 3, 2019
    Assignee: Essential Green Goodness LLC
    Inventors: Shamaya Chah, Nicholas Bart Magrone, Sr.
  • Patent number: 10201526
    Abstract: Compositions and methods for preventing and treating Neisseria gonorrhoeae infection with AR-12 alone or in combination with antibiotics are provided.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 12, 2019
    Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation Foundation
    Inventors: Jennifer Edwards, Alexander Zukiwski
  • Patent number: 10040813
    Abstract: Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: August 7, 2018
    Assignee: ACAHEALTH PHARMA & BIOTECH CO., LTD.
    Inventor: Rong-Tsun Wu
  • Patent number: 10016360
    Abstract: Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: July 10, 2018
    Inventors: Steven Elbogen, Don Wirtshafter
  • Patent number: 9895343
    Abstract: A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: February 20, 2018
    Assignee: GLIA, LLC
    Inventors: Kenneth I. Sawyer, Wei-wei Chang
  • Patent number: 9855223
    Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: January 2, 2018
    Assignee: Concordia University
    Inventors: Abhay Singh Chauhan, Eric Andrew Newenhouse, Armin Henry Gerhardt
  • Patent number: 9517215
    Abstract: This invention is related to dermal matrices and production method thereof, having within its structure micro particles having antioxidant agents with synergistic effects, providing speedy repair of the dermal tissue, used in chronic wound treatments, basically comprising the steps of preparing the dermal matrix system (11), forming micro particles (12), combining the micro particles with the dermal matrix system.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: December 13, 2016
    Assignee: T.C. EGE UNIVERSITESI
    Inventors: Kevser Ozgen Ozer, Evren Homan Gokce, Ipek Eroglu, Sakine Tuncay Tanriverdi
  • Patent number: 9402793
    Abstract: Use of UV-filters to stabilize resveratrol in topical cosmetic compositions and to improve the efficacy of topical cosmetic skin whitening compositions containing resveratrol as skin whitening agent.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: August 2, 2016
    Assignee: DSM IP ASSETS B.V.
    Inventors: Mareike Beck, Kerstin Den Brave, Juana-Lucia Flores-Candia, Yingzi Lu
  • Patent number: 9228999
    Abstract: A method for screening an active agent intended for preventing or combating the cutaneous signs resulting from a non-pathological impairment of barrier function, which includes the selection of active agents that stimulate the expression of the ceramide transport protein CERT in cultured human keratinocytes.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: January 5, 2016
    Assignee: CHANEL PARFUMS BEAUTE
    Inventors: Alexandra D'Arcangelis, Elena Fedorova
  • Patent number: 9163049
    Abstract: The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: October 20, 2015
    Assignees: PIERRE FABRE DERMO-COSMETIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Jean-Philippe Houlmont, Isabelle Rico-Lattes, Emile Perez, Pascal Bordat
  • Patent number: 9060962
    Abstract: Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: June 23, 2015
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Robert A. Lodder, Lisa A. Cassis
  • Publication number: 20150147314
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20150132373
    Abstract: A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ?95% purity and resveratrol is of ?98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in crystal powder to optimize oral intake in the form of capsule or tablet. In small dosage, it should preferably include a minimum of 5 mg of lycopene and 10 mg of resveratrol. Various range of ratios of lycopene:resveratrol are provided for specific therapeutic purposes including 1:4 for symptomatic relief of arthritis, 1:2 for inhibiting melanoma or carcinoma malignancy, and 1:3 for inhibiting hyperlipoidemia. Generally, our dietary supplement composition may be used as an agent for anti-ageing, anti-oxidative, inhibiting cardiovascular diseases, relieving menopause symptoms and remission of post-operative cancer patients.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventor: Kun Lung HSIEH
  • Publication number: 20150132400
    Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Applicant: Echo Pharmaceuticals B.V.
    Inventors: Jan Albert De Vries, Maria Vanesa Fernandez Cid, Ana Maria Heredia Lopez
  • Patent number: 9029424
    Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: May 12, 2015
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Jefferey Reinhardt, Samuel Manoharan Thomas, Krishnamani Jayaraman
  • Patent number: 9029320
    Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Red Mountain Med Spa, LLC
    Inventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
  • Publication number: 20150126595
    Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
    Type: Application
    Filed: December 4, 2014
    Publication date: May 7, 2015
    Inventor: Nicole SMITH
  • Patent number: 8993636
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Alcon Pharamceuticals, Ltd.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Patent number: 8980954
    Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 17, 2015
    Assignee: STC.UNM
    Inventors: David L. Vander Jagt, Lorraine M. Deck
  • Publication number: 20150072012
    Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
  • Patent number: 8968784
    Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: March 3, 2015
    Assignee: Research Foundation of the City University of New York
    Inventors: George John, Praveen Vemula
  • Publication number: 20150057342
    Abstract: Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 26, 2015
    Inventors: Zohar KOREN, Eyal BALLAN, Itamar BOROCHOV, Shay Avraham SARID
  • Publication number: 20150050366
    Abstract: Some embodiments of a system or method for applying a barrier composition to a targeted skin surface can be used to as a preventative measure to reduce the likelihood of transmission of microbial entities from an external source (e.g., a floor surface or another surface) to the targeted skin surface.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 19, 2015
    Inventors: Aner Vlodaver, Benhoor Soumekh, Smarajit Mitra, Sumita B. Mitra
  • Publication number: 20150037398
    Abstract: A molecule mixture comprising an amphipathic molecule of type A, which has an overall positive charge in the hydrophilic region, an amphipathic molecule of type B and a polyphenol C, the method for producing the molecule mixture, and the use thereof. The molecules of types A and B are present at a molecular ratio of A:B of 1(±0.2):1(±0.2) mol/mol. A method for producing the mixture and the use is also disclosed.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 5, 2015
    Applicant: FORSCHUNGSZENTRUM JÜLICH GMBH
    Inventors: Agnes Csiszar, Christian Kleusch, Bernd Hoffmann, Rudolf Merkel
  • Publication number: 20150030587
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 29, 2015
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Publication number: 20150030683
    Abstract: In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway are provided. In certain embodiments the methods involve administering, or causing to be administered, to a subject in need thereof certain formulations comprising or more active agent(s) selected from the group consisting of tropisetron disulfiram, honokiol, nimetazepam, and/or derivatives or analogs thereof.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 29, 2015
    Inventors: Varghese John, Dale E. Bredesen, Stelios Tzannis
  • Publication number: 20150030579
    Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Ann FOWLER, Angelika FRIEDEL, Darko KNUTTI, Karin KURATLI, Daniel RAEDERSTORFF, Ying WANG-SCHMIDT, Karin WERTZ
  • Publication number: 20150024060
    Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 22, 2015
    Applicant: BIOACTIVES LLC
    Inventors: Doddabele L. Madhavi, Daniel I. Kagan
  • Publication number: 20150025104
    Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 22, 2015
    Applicant: BIOACTIVES LLC
    Inventors: Doddabele L. Madhavi, Daniel I. Kagan
  • Patent number: 8927528
    Abstract: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 6, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Josef Miller, Colleen LePrell, Jochen Schact, Diane Prieskorn
  • Publication number: 20150004242
    Abstract: Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Inventors: Zhenjia Wang, Jaehyung Cho, Asrar Malik
  • Publication number: 20150004237
    Abstract: Provided are cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers include cellulose esters of formula I: wherein n of the ?-carboxyalkanoyl group, is 3, 4, 6, or 8 to provide a ?-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from: a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ?-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n=1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone.
    Type: Application
    Filed: January 9, 2013
    Publication date: January 1, 2015
    Inventors: Kevin J. Edgar, Bin Li, Lynne Taylor, Grace Ilevbare, Stephanie M. Williams, Haoyu Liu
  • Publication number: 20150005391
    Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.
    Type: Application
    Filed: June 24, 2014
    Publication date: January 1, 2015
    Inventor: Jeptha N. Cole
  • Publication number: 20140378539
    Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 25, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
  • Publication number: 20140378424
    Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.
    Type: Application
    Filed: December 31, 2012
    Publication date: December 25, 2014
    Inventors: Alexey G Ryazanov, Alexander V. Chikunov
  • Publication number: 20140377382
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 25, 2014
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20140371328
    Abstract: The present invention relates to topical compositions comprising resveratrol in a liquid crystal gel network formed by a phosphate ester surfactant and a co-emulsifier. The present invention also relates to the process to make such compositions.
    Type: Application
    Filed: September 24, 2012
    Publication date: December 18, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Juana Lucia Flores-Candia, Karina Hecker
  • Publication number: 20140363502
    Abstract: The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to a recipient, increases the concentration or activity of a survival/longevity gene product and/or decreases the concentration or activity of a gene product that induces or causes cellular damage. Most preferably, the resveratrol-stabilizing composition will comprise the chelator phytic acid (inositol hexaphosphate; IP6), hyaluronic acid, and vitamin D. The invention further pertains to the use of such compositions in the treatment or prevention of cancer, cardiovascular disease, diseases associated with aging, and other conditions and illnesses.
    Type: Application
    Filed: August 25, 2014
    Publication date: December 11, 2014
    Inventor: William F. Sardi
  • Patent number: 8906960
    Abstract: A transdermal fluid is provided wherein the main ingredient is tocotrienol and curcumin is added to enhance the anti-cancer effects of tocotrienols. The composition is useful for the treatment or prevention of a cancer, a tumor or an inflammatory disorder, particularly breast cancer.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 9, 2014
    Assignee: Malaysian Palm Oil Board
    Inventors: Kalanithi Nesaretnam, Kanga Rani Selvaduray
  • Publication number: 20140348761
    Abstract: A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol, and PPG-1-PEG-9 lauryl glycol ether. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 27, 2014
    Applicant: Colgate-Palmolive Company
    Inventors: Regina Hourigan, Jeffery Mastrull, Jairajh Mattai, James Masters
  • Publication number: 20140341967
    Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
    Type: Application
    Filed: July 10, 2014
    Publication date: November 20, 2014
    Inventors: Eugene Rex Cooper, David Maxwell Kleinman, Andrew Loxley, Mark Mitchnick
  • Publication number: 20140341818
    Abstract: A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol, and dimethyl isosorbide. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 20, 2014
    Applicant: COLGATE-PALMOLIVE COMPANY
    Inventors: Regina Hourigan, Jeffrey Mastrull, Jairajh Mattai, James Masters
  • Publication number: 20140336254
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 13, 2014
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Patent number: 8859021
    Abstract: The present invention relates to a method for treating, preventing and improving the condition and/or aesthetic appearance of aging skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, through meroterpene induced gene manipulation.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 14, 2014
    Assignee: Sytheon
    Inventor: Ratan K. Chaudhuri
  • Publication number: 20140303260
    Abstract: A pharmaceutical composition for administering a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof to a subject. The absorption of resveratrol occurs through the subject's buccal/sublingual membranes, thereby by-passing first pass metabolism by the liver.
    Type: Application
    Filed: October 17, 2012
    Publication date: October 9, 2014
    Inventors: Ross Stewart Grant, Keith Lindbeck